health π¬ FDA accepts daraxonrasib application for cancer
The FDA has accepted the New Drug Application for daraxonrasib for previously treated metastatic pancreatic adenocarcinoma. This filing came from Revolution Medicines, after presenting RASolute 302 data at ASCOβs Plenary Session. The trial showed a median overall survival of 13.2 months versus 6.7 months with chemotherapy, reported on August 5, 2026. This significant result signals confidence as the company rapidly expands its clinical presence. The FDA also granted Breakthrough Therapy Designation for daraxonrasib in metastatic NSCLC.